Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.
Aim(s): Our aim was to identify clinico-biological and histological markers of response to everolimus.
Materials and methods: We retrospectively reviewed 53 patients with NETs treated by everolimus. Markers of mTOR pathway (p-p70S6K) and angiogenesis (endoglin, CD34) were studied by immunohistochemistry. Prognostic factors of PFS were studied by Kaplan Meier analysis. Good responders (PFS> 12 months) were compared to poor responders (PFS
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Noura Benslama
To read results and conclusion, please login ...
Further abstracts you may be interested in